PubMed:25163405 / 1266-1934 JSONTXT

{"project":"PubMed_Structured_Abstracts","denotations":[{"id":"T4","span":{"begin":0,"end":668},"obj":"RESULTS"}],"text":"For the primary end point, epinastine showed superiority to placebo for the inhibition of ocular itching and conjunctival hyperemia induced at 4 hours after the dose (equivalent to 4-times-daily dosing). For the secondary end points, epinastine significantly inhibited itching and conjunctival hyperemia induced at 15 minutes and 8 hours after the dose (equivalent to 2-times-daily dosing) compared with placebo. In addition, epinastine demonstrated noninferiority to olopatadine for ocular itching and conjunctival hyperemia. No adverse drug reactions or serious adverse events were reported throughout the study, indicating that epinastine has a good safety profile."}

{"project":"maxiaofeng52_800_3","denotations":[{"id":"T10","span":{"begin":27,"end":37},"obj":"CI"},{"id":"T11","span":{"begin":234,"end":244},"obj":"CI"},{"id":"T12","span":{"begin":426,"end":436},"obj":"CI"},{"id":"T13","span":{"begin":631,"end":641},"obj":"CI"},{"id":"T17","span":{"begin":60,"end":67},"obj":"CI"},{"id":"T18","span":{"begin":404,"end":411},"obj":"CI"},{"id":"T22","span":{"begin":468,"end":479},"obj":"CI"}],"text":"For the primary end point, epinastine showed superiority to placebo for the inhibition of ocular itching and conjunctival hyperemia induced at 4 hours after the dose (equivalent to 4-times-daily dosing). For the secondary end points, epinastine significantly inhibited itching and conjunctival hyperemia induced at 15 minutes and 8 hours after the dose (equivalent to 2-times-daily dosing) compared with placebo. In addition, epinastine demonstrated noninferiority to olopatadine for ocular itching and conjunctival hyperemia. No adverse drug reactions or serious adverse events were reported throughout the study, indicating that epinastine has a good safety profile."}

{"project":"wangzhuo19_800_3","denotations":[{"id":"T10","span":{"begin":60,"end":67},"obj":"CI"},{"id":"T11","span":{"begin":404,"end":411},"obj":"CI"},{"id":"T15","span":{"begin":27,"end":37},"obj":"CI"},{"id":"T16","span":{"begin":234,"end":244},"obj":"CI"},{"id":"T17","span":{"begin":426,"end":436},"obj":"CI"},{"id":"T18","span":{"begin":631,"end":641},"obj":"CI"},{"id":"T28","span":{"begin":468,"end":479},"obj":"CI"}],"text":"For the primary end point, epinastine showed superiority to placebo for the inhibition of ocular itching and conjunctival hyperemia induced at 4 hours after the dose (equivalent to 4-times-daily dosing). For the secondary end points, epinastine significantly inhibited itching and conjunctival hyperemia induced at 15 minutes and 8 hours after the dose (equivalent to 2-times-daily dosing) compared with placebo. In addition, epinastine demonstrated noninferiority to olopatadine for ocular itching and conjunctival hyperemia. No adverse drug reactions or serious adverse events were reported throughout the study, indicating that epinastine has a good safety profile."}